Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma.
Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma.
复制标题
高剂量扑热息痛和卡莫司汀治疗转移性黑色素瘤患者的 I 期试验。
DOI:
10.1097/00008390-200304000-00013
复制
发表时间:
2003
影响因子:
2.2
通讯作者:
Chapman,PaulB
中科院分区:
文献类型:
--
作者:
Wolchok,JeddD;Williams,Linda;Pinto,JohnT;Fleisher,Martin;Krown,SusanE;Hwu,Wen-Jen;Livingston,PhilipO;Chang,Christine;Chapman,PaulB
Reduced glutathione (GSH) production by tumour cells has been proposed as a mechanism for resistance to alkylating agents. High levels of paracetamol can deplete intracellular GSH. We conducted a phase I trial of high dose paracetamol and carmustine (BCNU) in patients with advanced malignant melanoma to determine the optimal biological dose and the maximum tolerated dose (MTD) with the goal of increasing sensitivity to BCNU by GSH depletion. Groups of three to five patients received escalating doses of paracetamol (10, 15 or 20 g/m 2) every 3 weeks. Every other cycle, BCNU (10 mg/m 2) was given 6.5 h after administration of paracetamol and 45 min before a 20 h infusion ofN-acetylcysteine. Once the MTD for paracetamol had been determined, the dose of BCNU was sequentially escalated in subsequent cohorts to 150 mg/m 2. GSH levels were measured in peripheral blood mononuclear cells (PBMCs) and, when available, in tumour biopsies. The MTD of paracetamol was 15 g/m 2. The dose of BCNU was safely escalated to 150 mg/m 2. The most common toxicity was grade II nausea/vomiting. At 15 g/m 2, peak paracetamol levels (median 253 μg/ml) were reached between 1 and 4 h. No changes in GSH levels in PBMCs were seen. There were two partial responses, including a dramatic decrease in hepatic metastases. Treatment of melanoma patients with paracetamol (15 g/m 2) every 3 weeks and BCNU (150 mg/m 2) every 6 weeks is safe. The observation of two partial responses has led to a phase II study to evaluate treatment with high dose paracetamol alone or in combination with BCNU.
登录
查看更多内容
影响因子:
5.4
作者:
H. Thiesen;Z. Bösze;L. Henry;P. Charnay
通讯作者:
P. Charnay
DOI:
10.1073/pnas.84.19.6845
发表时间:
1987
影响因子:
11.1
作者:
S. Tong;P. Luciw;B. Peterlin
通讯作者:
B. Peterlin
影响因子:
5.3
作者:
N. Speck;D. Baltimore
通讯作者:
D. Baltimore
DOI:
10.1073/pnas.86.7.2336
发表时间:
1989-04-01
影响因子:
11.1
作者:
OSBORN, L;KUNKEL, S;NABEL, GJ
通讯作者:
NABEL, GJ
影响因子:
--
作者:
Zoller,MJ;Smith,M
通讯作者:
Smith,M